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Familial hypercholesterolemia (FH) is an autosomal
dominant disease which results in 2-3-fold elevated
cholesterol levels and in accelerated atherosclerosis. FH
is caused by small mutations or larger rearrangements
in the low-density lipoprotein receptor (LDLR). Here, we
report that screening the LDLR gene in a Swiss family
(n = 15) with clinical symptoms of FH by combined sin-
gle strand conformation polymorphism and long-dis-
tance PCR identified a novel 1.3 kb deletion in the LDLR.
The deletion eliminated exon 4 of the LDLR presumably
by recombination between two identical 25 bp repeats
present in intron 3 and 4. The 25 bp sequence in intron 3
is part of an Alu repeat, whereas no homology to Alu re-
peats was found for the intron 4 region. This 1.3 kb LDLR
deletion allele cosegregated with elevated cholesterol
levels over three generations. Even on high-dose statin
therapy, carriers of the deletion averaged 1.6 times
higher cholesterol levels and 1.9 times higher apo-
lipoprotein B-100 (apoB-100) levels than non-carriers
who had lipid and apoB-100 levels within the range of
the Swiss population. Most affected members of the
first and second generation of this family had experi-
enced a first myocardial infarction (MI) before the age of
55 years and most LDLR gene deletion carriers older
than 40 years showed severe coronary artery disease
(CAD). Hence, we conclude that deletion of exon 4 in the
LDLR gene drastically decreases low-density lipopro-
tein binding leading to severe hypercholesterolemia.
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Introduction
Cardiovascular disease accounts for the majority of
morbidity and mortality in the western countries. Most
forms of cardiovascular disease involve atherosclerotic
vascular changes in the coronary, cerebral, renal, and
peripheral circulation leading to angina pectoris, myo-
cardial infarction (MI), stroke, renal failure, and clau-
dication. Hypercholesterolemia is a well recognized
risk factor for atherosclerosis of central and peripheral
arteries (1). In the western countries, one of the most
common genetic disorders which results in elevated
cholesterol levels is familial hypercholesterolemia
(FH). This autosomal dominant disorder with a preva-
lence of about 1/500 in the western countries is caused
by mutations in the (LDLR) gene (2). The LDLR defect
impairs the catabolism of LDL and results in elevation
of plasma LDL-cholesterol (2). Untreated heterozygous
FH patients have 2–3 times elevated cholesterol levels
and have a 100-fold increased risk to die from coronary
artery disease (CAD) before the age of 40 years, while a
5-fold increased risk is still observed for patients over
40 years (3).
Over 770 different mutations in the LDLR gene have
been reported (http://www.ucl.ac.uk/fh) which are
more or less equally spread over the entire gene. The
majority of mutations in the LDLR gene are nucleotide
substitutions or small deletions and insertions; how-
ever, about 12% of all entries in the LDLR database are
deletions or insertions larger than 1 kb. Two hundred
and sixty-nine LDLR mutations (Germany: 95, France:
82, Italy: 69 and Austria: 20) are known in Central Eu-
rope (http://www.ucl.ac.uk/fh). In Switzerland, only
2 mutations are known so far: V408M and P664L (4).
We decided to screen for the LDLR in a family with
clinical manifestation of FH by single strand conforma-
tion polymorphism (SSCP) to detect small mutations,
and by long-distance PCR (5) to detect larger re-
arrangements (6). Using this screening strategy we de-
tected a 1333 bp deletion of exon 4 in the LDLR gene,
ranging from intron 3 to intron 4, which cosegregated
with elevated cholesterol levels in a Swiss family with
severe hypercholesterolemia.
Materials and Methods
Fifteen members of a family with clinical manifestations of FH
were enrolled from the outpatient clinic of the University Hos-
pital in Zurich. There was a family history of premature car-
diovascular disease with elevated cholesterol levels. Patients
underwent a medical history- and physical examination. Stan-
dard 12-lead electrocardiography and exercise testing were
done if appropriate. Blood samples were taken for blood lipid
profile and genetic testing for LDLR gene defects. The study
was approved by the local Ethics Commitee and all patients
included gave informed consent to participate.
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DNA was extracted with a Qiamp® DNA Blood Mini Kit
(QIAGEN, Venlo, The Netherlands). Long-distance PCR (Ex-
pand™ long template PCR System: Roche, Basel, Switzerland)
was performed as previously described (5) with minor modifi-
cations on a GeneAmp® PCR System 9600 (Applied Biosys-
tems, Foster City, USA): The MgCl2 concentration were
2.75 mM for amplification of fragments 1, 4 and 5, and
2.25 mM for fragments 2 and 3. An annealing temperature of
62 °C for fragments 1, 2 and 4, and 58 °C for fragments 3 and 5
was used. Elongation times were 13 min for fragments 2, 4
and 5, 17 min for fragment 1, and 11 min for fragment 3. The
total number of cycles was 30. The first 15 cycles were realized
by the parameters defined above followed by 15 cycles with
increased elongation time (15 s per cycle). PCR products were
analyzed on a 0.8% agarose gel. Running conditions were 100
V during 6 h followed by ethidium bromide staining and ultra-
violet (UV) detection.
To define the exact breakpoints of the deletion, we ampli-
fied the region between intron 1 (primer 4 (P4)) and 5 (P2), in-
tron 2 (P5) and 5 (P2), intron 3 (P6) and 5 (P2), and between
exon 4 (P7) and intron 5 (P2) (for primers see Table 1). Fifty µl
PCR reactions included 400 nanomolar (nM) of the upper and
lower primer, 500 micromolar (µM) 2’-deoxynucleotide 5’-
triphosphate (dNTP’s), 2.5 units Expand™ long template en-
zyme mixture in 1× Expand™ long template buffer 3, and ap-
proximately 400 ng genomic DNA. The DNA was amplified
with an initial denaturation step of 94 °C for 2 min, followed by
30 cycles at 94 °C for 10 s, 60 °C for 30 s, and 68 °C for 8 min,
followed by a final elongation step at 68 °C for 7 min. PCR
products were analyzed on a 0.8% agarose gel.
For routine detection of the exon 4 deletion, a 2.4 kb frag-
ment was amplified using an upper primer (P1) in intron 3 and
a lower primer in intron 5 (P2). The intron 3 to intron 5 region
was amplified in a 50 µl reaction containing 400 nM solution of
each primer, 500 µM each dNTP, 2.5 units of Expand™ long
template Enzyme Mix in buffer 3 of the Expand™ long tem-
plate PCR system. The PCR was performed under the follow-
ing conditions: an initial denaturation step of 2 min at 94 °C,
followed by 15 cycles for 10 s at 94 °C, 30 s at 60 °C, and 4 min
at 68 °C. Another 15 cycles were performed with the same pa-
rameters, except that in every elongation step the incubation
time was increased by 15 s.
To define the deletion breakpoints, the PCR fragment from
the wild-type and the mutant allele (PCR with primers P1 and
P2) was subcloned with an Original TA Cloning® Kit according
to the manufacturer’s instructions (Invitrogen, Carlsbad,
USA). The plasmid isolation was performed with a QIAprep
Spin Miniprep Kit (QIAGEN, Venlo, The Netherlands). Plasmid
inserts were then sequenced on an ABI Prism 310 (Applied
Biosystems, Foster City, USA), with the chemistry and running
conditions recommended by the manufacturer. Downstream
sequencing primer was P1, upstream sequencing primer was
P3.
Plasma total cholesterol and triglyceride values were deter-
mined on a Hitachi 747 (Roche, Basel, Switzerland), high-den-
sity lipoprotein (HDL)-cholesterol and apolipoprotein B-100
(apoB-100) values were measured on a Cobas Integra 700
(Roche, Basel, Switzerland) with standard methods supplied
by the manufacturer.
Results
Initially, the deletion in the LDLR was detected by two
independent long-distance PCR amplifications in four
family members. First, in the amplified fragment en-
compassing the promotor region to exon 5 of the LDLR
gene and second, in the PCR product encompassing
the genomic region from exon 2 to exon 10 (data not
shown). Since both amplifications detected the dele-
tion, the deletion breakpoint must be located between
exon 2 and exon 5 of the LDLR gene.
To scan for the exact breakpoints of the deletion, PCR
products of different length were amplified on the ge-
nomic DNA from a FH sibling (Figure 1). The PCR prod-
ucts were designed to span from introns 1 to 5, 2 to 5, 3
to 5, and from exon 4 to intron 5, dissecting the region
into four smaller stretches. Amplification of introns
1–5 and 2–5 produced two products representing the
wild-type and the deletion allele, whereas amplifica-
tion of intron 3 to intron 5 and amplification of exon 4
to intron 5 resulted in only one signal. Hence, the
5´deletion breakpoint is possibly located in intron 3,
and due to the approximate size of the deletion (1.3 kb)
the 3´ deletion breakpoint should be located in intron 4.
To determine the exact breakpoints of the deletion,
we subcloned the amplified wild-type and deletion al-
lele from an affected sibling into pCR®2.1. We amplified
the region between intron 3 and intron 5, which re-
sulted in a wild-type product of 2399 bp and in a prod-
uct of 1066 bp harboring the deletion. Sequencing of
the two subclones revealed that the shorter allele
lacked 1333 bp deleting the entire coding region for
exon 4. At the deletion breakpoints, two identical 25 bp
direct repeats with the sequence TTTTTGAGATG-
GAGTCTCACTCTGT were present (Figure 2) suggest-
Table 1 Oligonucleotides used in this study.
Primer 5‘ position* Sequence** 3‘ position*
P1 75540 CCTACCTACTTTCTGGAATAAATCTG 75515
P2 73143 CGCCCTCTGGCTTCACAAATC 73163
P3 73784 TGGTGAAACCCCATCTCTACTAAATAG 73810
P4 79759 ATAGACACAGGAAACGTGGTCA 79738
P5 77294 CAGTGGGTCTTTCCTTTGAGTGACA 77270
P6 74752 AATGGGCTGGTGTTGGGAGACT 74731
P7 74499 AACGACCCCGACTGCGAAGA 74480
*Positions are given according to the Homo sapiens chromo-
some 19 clone CTB-164O19 (GenBank Accession No. AC011485)
wherein the entire LDLR gene is present. **Sequences are
shown 5‘ to 3‘.
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ing that the deletion originated from illegitimate re-
combination.
To investigate if this exon 4 deletion in the LDLR was
responsible for hypercholesterolemia, we genotyped
15 family members for the exon 4 deletion and investi-
gated cosegregation of the deletion with hypercholes-
terolemia. To simplify genotyping, we established a
PCR which amplifies the region from intron 3 (849 bp
upstream of exon 4) to intron 5 (80 bp downstream of
exon 5) encompassing the exon 4 deletion. Amplifica-
tion of the wild-type allele produced a PCR product of
2.4 kb, whereas amplification of the allele with the exon
4 deletion produced a 1.1 kb product (Figure 3).
Over three generations, all carriers of the exon 4 dele-
tion, had markedly elevated total cholesterol, LDL-cho-
lesterol and apoB-100 levels despite cholesterol-lower-
ing therapy (mean: 8.2 mmol/l, 6.2 mmol/l and 1.7 g/l, n =
10), and only slightly elevated triglyceride levels (mean:
1.8 mmol/l, n = 10) (Table 2). Two previously not treated
carriers of the third generation had mean total choles-
terol, LDL-cholesterol, apoB-100, and triglyceride levels
of 10.2 mmol/l, 8.5 mmol/l, 2.2 g/l, and 1.5 mmol/l, re-
spectively (n = 2). In contrast, the non-affected siblings
had plasma lipid and apoB-100 levels in the range of the
Swiss population (mean: 5.0 mmol/l, 3.0 mmol/l, 0.9 g/l,
and 1.0 mmol/l, respectively, n = 3). It is noteworthy that
even on high-dose cholesterol-lowering therapy (sim-
vastatin 80 mg/d, atorvastatin 80 mg/d), carriers of the
exon 4 deletion had elevated cholesterol levels and
most of the carriers needed combined lipid-lowering
therapy and LDL-apheresis. Moreover, three affected
members of this family had experienced a premature MI
(patients no. 4, 5, and 6) and two more affected mem-
bers (no. 1 and 9, Figure 3) showed CAD as demon-
strated by angiography. These two subsequently under-
went percutaneous coronary intervention and coronary
artery bypass grafting.
Discussion
This study describes a novel exon 4 deletion in the
LDLR, which cosegregates over three generations with
Figure 1 Approximate localization of the deletion break-
points. The genomic region from intron 1–5 (lane 1), intron
2–5 (lane 2), intron 3–5 (lane 3), and exon 4 to intron 5 (lane 4)
was amplified and separated on an agarose gel (left side). A
schematic illustration of the experiment is shown on the right
side. These results indicate that the deletion breakpoints must
be localized in intron 3 and 4. Two signals appear at the am-
plification of the genomic sequence from intron 2–5, repre-
senting the wild-type allele (upper signal) and the allele that
carries the 1.3 kb deletion (lower signal). In lane 2, where the
genomic sequence from intron 3–5 was amplified, three sig-
nals are visible, whereas the signal in the middle supposedly
derives from unspecific amplification. The upper and lower
signals represent the wild-type (wt) and the deleted (del) al-
lele, respectively.
Figure 2 Schematic illustration of the exon 4 deletion break-
point area. At the breakpoints of the deletion, two identical
25 bp direct repeats are present. The upper and lower se-
quence stretches show wild-type sequences from intron 3 and
4, respectively, whereas the sequence in the middle repre-
sents the deleted allele. Asterisks indicate identical bases.
Figure 3 Genetic analysis of the Swiss family with a 1.3 kb
deletion. Top: Pedigree of the affected Swiss FH-patients. Half-
filled symbols indicate affected-, blank symbols denote non-
affected members of the family, whereas squares represent
males and circles females. The family member marked with a
slash has deceased after three cardiac infarctions. Cholesterol
levels at presentation are indicated in mmol/l below the sym-
bols. Patient numbering corresponds with Table 2. Patients
with severe CAD*, or MI**, respectively. Bottom: An ethidium
bromide-stained agarose gel is shown, prepared after genetic
testing of the exon 4 deletion. The signal, which migrates as a
2.4 kb fragment represents the PCR product of the wild-type
allele, and the signal at 1.1 kb represents the PCR-product of
the mutant allele.
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elevated cholesterol levels and with clinical manifesta-
tion of FH. Even on high-dose statin therapy, mean cho-
lesterol levels in affected members of the family still
averaged 1.6 times the level of the non-affected sib-
lings (8.2 mmol/l, n = 10vs. 5.0 mmol/l, n = 3).
Although the penetration of the exon 4 allele is high
and all carriers showed elevated cholesterol levels,
there are still interindividual differences in cholesterol
levels. For example, out of three siblings on high-dose
statin therapy who are all heterozygous for the exon 4
deletion, two showed clearly elevated cholesterol lev-
els (patient no. 1: 9.1 mmol/l and patient no. 4:
9.3 mmol/l total cholesterol; Table 2), whereas the third
sibling had only slightly elevated cholesterol levels (pa-
tient no. 3: 6.6 mmol/l). Intriguingly, all three siblings
had identical apolipoprotein E genotype (ε2/3) and
none had the familial defective apoB-100 mutation
(data not shown), both known factors to influence cho-
lesterol levels (7, 8). As was previously observed, there
are other genetic and environmental factors that affect
cholesterol levels in FH patients (9–11). Kajinami et al.
(12) reported that plasma cholesterol levels in some
heterozygotes with an exon 2–3 deletion was essen-
tially normal, although the receptor affinity for LDL-
particles was reduced to 40% in homozygotic carriers.
Vega et al. (9) reported that such an inconsistent pene-
tration of the FH mutation could originate from
changes in LDL input rates and LDL catabolic rates. Al-
though cholesterol levels varied between carriers of
the exon 4 deletion in the Swiss family, no carrier
showed normal cholesterol levels, suggesting that the
penetration of the exon 4 deletion is high and that the
exon 4 deletion results in a receptor-deficient pheno-
type.
Exon 4 codes for three of the seven cystein-rich lig-
and-binding repeats of the LDLR and plays an essential
role in receptor binding activity. In the LDLR gene, ex-
ons 2–6 code for the seven ligand-binding domains,
whereas exon 4 alone codes for repeats number 3–5
which are in the center of the ligand-binding domain
(13). Transcription from the exon 4 deletion allele is
predicted to lead to an mRNA lacking exon 4, consider-
ing that the splicosome will use the splicing donor site
in intron 3 and use the next available acceptor site in in-
tron 4. Translation of this truncated mRNA is predicted
not to prematurely terminate through a frameshift or
stop mutation but rather to translate a LDLR lacking the
127 amino acids of exon 4. This truncated LDLR miss-
ing three ligand-binding repeats is predicted to have
reduced or absent binding capacity since it has been
shown that deletion of the ligand-binding domains re-
sults in decreased binding capacity for apoB-100 (12,
14, 15). For example, in a similar mutation where exon
5 is deleted which codes for one cysteine-rich ligand-
binding repeat, the receptor lost its function to bind
apoB-100 containing LDL (14). Furthermore, Esser et al.
(16) analyzed LDLRs with several truncated ligand-
binding domains in transfected COS-M6 cells for bind-
ing to LDL. They found that consecutive deletion of
ligand-binding repeats correlated with decreased
receptor-binding to LDL. When the receptor lacked
binding repeats 1–3, LDL-binding was reduced to 31%
of the wild-type receptor. However, when binding re-
peats 1–5 were absent, ligand-binding was totally
Table 2 Patient data.
Patient Sex Age Drug Long Chol. total HDL Chol/ LDL Tg ApoB-100
no. treat- PCR (mmol/l) (mmol/l) HDL (mmol/l) (mmol/l) (g/l)
ment
1 F 40 + del 9.1 1.5 6.1 6.9 1.6 1.8
2 M 39 – wt 4.8 1.5 3.3 3.0 0.9 0.9
3 M 38 + del 6.6 1.5 4.4 4.8 0.8 1.2
4 M 36 + del 9.3 1.1 8.4 6.0 4.9 1.9
5 M 74 + del 9.2 1.6 5.8 6.5 2.5 1.9
6 F 47 + del 9.2 0.9 10.8 7.4 2.2 2.2
7 F 26 – del 8.4 0.7 11.7 6.8 1.9 2.0
8 F 29 + del 7.7 1.2 6.4 5.8 1.6 1.7
9 F 58 + del 8.7 1.0 8.7 7.0 1.6 1.9
10 F 84 – wt 5.9 1.7 3.6 3.7 1.3 1.0
11 M 39 – del 11.9 1.3 9.5 10.1 1.1 2.4
12 M 36 + del 9.9 0.9 11.5 8.3 1.7 2.1
13 M 51 + del 6.5 1.6 4.1 4.7 0.6 1.4
14 M 48 + del 6.1 1.7 3.6 4.2 0.5 1.2
15 F 25 – wt 4.2 1.6 2.7 2.3 0.7 0.8
∅ del untreated (n=2) 10.2 1.0 10.6 8.5 1.5 2.2
∅ del treated (n=10) 8.2 1.3 7.0 6.2 1.8 1.7
∅ wt (n= 3) 5.0 1.6 3.2 3.0 1.0 0.9
Clinical data of investigated FH family members: Values are
actual concentrations of the respective parameters. The pa-
tient-numbering corresponds with Figure 3. Column 4 shows
whether drug treatment was realized (+) or not (–). Chol = cho-
lesterol, Tg = triglyceride. The last three rows resume aver-
aged values of 3 wild-type (wt)-, 10 affected and treated (del
treated)- and 2 affected but not treated (del untreated) family
members.
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abolished (16). From these data we conclude that the
exon 4 deletion receptor, which lacks the ligand-bind-
ing repeats 3, 4, and 5, has markedly reduced or absent
ligand-binding activity. As mentioned before, this is
supported by clinical data from the Swiss family with
hypercholesterolemia where the exon 4 deletion
cosegregates with highly elevated cholesterol levels.
Intriguingly, this is not the case for all LDLR mutations
(17).
The exon 4 deletion in the LDLR gene is flanked by
two 25 bp direct repeats suggesting that illegitimate re-
combination between the two repeats caused the dele-
tion. Two other deletions in the LDLR were reported to
originate from recombination, both lacking exon 5: FH-
Aarhus-3 (18) and FH-Paris-1 (= FH626) (14) which is
also described as FH London-2(19). Investigation of the
deletion breakpoints in these alleles revealed that re-
peats belonging to the Alu families were present on
each side of the deletion (14,18). Such a mechanism
may have created the deletion of exon 4, since at the
deletion breakpoints two 25 bp direct repeats are pre-
sent which are part of several Alu subfamilies (20). The
region of the deletion breakpoint in intron 3 contains a
sequence stretch that shows homology with Alu repeat
subfamilies Sc, Sg, Sx, and Y wherein the direct repeat
is present. The region in intron 4 lacks homology with
Alu repeats, however, the 25 bp direct repeat is identical
to intron 3, suggesting that this short repeat triggered
recombination and deletion of exon 4 in the LDLR.
In summary, this study shows an exon 4 deletion in
the LDLR that cosegregates with hypercholesterolemia
and clinical symptoms of FH. The severe phenotype of
this deletion indicates that lack of the three ligand-
binding domains encoded by exon 4 results in a recep-
tor-deficient phenotype.
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